Ronald Fleming
Seminars
Tuesday 13th October 2026
The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example
2:30 pm
- Understanding the MoA of T-DXd and potential for T-DXd to move from advanced to early oncology settings
- Identifying rationale-driven research to identify combination partners complimentary to T-DXd mechanism
- Reviewing clinical data of T-DXd from late-line HER2+ metastatic breast and gastric cancer to first-line approval combination therapy in HER2+ metastatic breast cancer and earlier-line metastatic gastric cancer settings
Tuesday 13th October 2026
Roundtable Discussion: Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance
3:30 pm
- Exploring the impact of ADC combinations on the oncology treatment landscape: Will combination therapies become the norm as more ADCs progress to earlier-line patient therapies?
- Debating the need for novel and out-the-box combination partners to enhance the clinical impact of ADC combination therapies
- Breaking down strategy and potential of ADC sequencing to best position ADCs for maximized clinical impact in patient sub-populations
